Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | VKORC1 | Q9BQB6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | OSBP | P22059 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000889 | 1.00 | ACHE (0.55) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL30249555 | 1.00 | ACHE (0.55) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL11305967 | 1.00 | ACHE (0.55) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL11305964 | 1.00 | ACHE (0.55) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL5823579 | 0.98 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL15970483 | 0.88 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL15970519 | 0.88 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL14248440 | 0.88 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL30555857 | 0.88 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA | |
| SCHEMBL31611507 | 0.88 | ACHE (0.56) | ACHEBACE1PTPN1PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200299735-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2020-09-24 | — | — | US | claimed |
| WO-2018144996-A1 | METABOLIC ENGINEERING FOR MICROBIAL PRODUCTION OF TERPENOID PRODUCTS | Manus Bio, Inc. (US) | 2018-08-09 | — | — | WO | claimed |
| US-20150299742-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2015-10-22 | — | — | US | claimed |
| US-20100210017-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2010-08-19 | — | — | US | claimed |
| EP-2126042-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | The Regents of the University of Colorado (US) | 2009-12-02 | — | — | EP | claimed |
| WO-2008089102-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-07-24 | — | — | WO | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | THE BROAD INSTITUTE, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250376656-A1 | MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-12-11 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250179576-A1 | MICROBIAL SIGNATURES OF AUTISM SPECTRUM DISORDER | PITON THERAPEUTICS, INC. (US) | 2025-06-05 | — | — | US | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| US-20100210017-A1 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2010-08-19 | — | — | US | disclosed |
| EP-2126042-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | The Regents of the University of Colorado (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| WO-2008089102-A2 | COMPOSITIONS AND METHODS FOR ENHANCING TOLERANCE FOR THE PRODUCTION OF ORGANIC CHEMICALS PRODUCED BY MICROORGANISMS | REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | ACHE 4135/4885BACE1 3996/4885PTPN1 1431/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | ACHE 2942/4885BACE1 3039/4885PTPN1 3029/4885 |
| US-12577526-B2 | Massively parallel on-chip construction of synthetic microbial communities | STUB1, SAMM50, CD14 | ACHE 2270/4885BACE1 2340/4885PTPN1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.